Keywords: dose escalation; dose optimization; psoriasis; secukinumab; AE; adverse event; PASI; Psoriasis Area and Severity Index; PASI-75; 75% reduction from baseline PASI score; PGA; Physician Global Assessment;
مقالات ISI (ترجمه نشده)
مقالات زیر هنوز به فارسی ترجمه نشده اند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
در صورتی که به ترجمه آماده هر یک از مقالات زیر نیاز داشته باشید، می توانید سفارش دهید تا مترجمان با تجربه این مجموعه در اسرع وقت آن را برای شما ترجمه نمایند.
Keywords: asimadoline; atopic dermatitis; emerging agents; fezakinumab; hypocholrous acid; omiganan; secukinumab; tapinarof; AD; atopic dermatitis; AE; adverse effect; AhR; aryl hydrocarbon receptor; AMP; antimicrobial peptide; EFA; essential fatty acids; HOCl; hyp
Keywords: Psoriasis; psoriatic arthritis; autoantigens; IL-17; IL-23; secukinumab; ixekizumab; brodalumab; tildrakizumab, guselkumab, and risankizumab; ADAMTSL5; A disintegrin-like and metalloprotease domain containing thrombospondin type 1 motif-like 5; AMP; Antim
Keywords: Psoriasis; Psoriatic arthritis; Infection; Secukinumab; Ixekizumab; Brodalumab;
Keywords: Biologics; Dermatology; Etanercept; Adalimumab; Infliximab; Ustekinumab; Secukinumab; IVIG;
Actualisation 2018Â des recommandations de la Société française de rhumatologie (SFR) pour la prise en charge en pratique courante des malades atteints de spondyloarthrite
Keywords: Spondyloarthrite; Spondylarthrite ankylosante; Rhumatisme psoriasique; Traitement; Rééducation; Ãducation thérapeutique; AINS; Biomédicaments; Anti-TNF; Ustekinumab; Secukinumab; Chirurgie; Recommandations;
2018 update of French Society for Rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis
Keywords: Spondyloarthritis; Ankylosing spondylitis; Psoriatic arthritis; Treatment; Rehabilitation; Therapeutic patient education; NSAIDs; Biologics; TNFα antagonists; Ustekinumab; Secukinumab; Surgery; Recommendations;
Effect of secukinumab on quality of life and psoriasis-related symptoms: A comparative analysis versus ustekinumab from the CLEAR 52-week study
Keywords: cumulative benefit; itching; pain; psoriasis; quality of life; scaling; secukinumab; AUC; area under the curve; CI; confidence interval; DLQI; Dermatology Life Quality Index; HRQoL; health-related quality of life; MCID; minimal clinically important differ
ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [II]: agents targeting interleukins, immunoglobuli
Keywords: Anakinra; Brodalumab; Canakinumab; Eculizumab; Infection; Ixekizumab; Prevention; Rilonacept; Secukinumab; Tocilizumab;
Secukinumab in psoriasis patients with prior ustekinumab treatment: Results of a single-center experience
Keywords: biologics; psoriasis; secukinumab; switch; ustekinumab;
The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24-week, randomized, double-blind, placebo-controlled phase 3b study
Keywords: clear or almost clear skin; clinical trial; phase 3; prospective; scalp psoriasis; secukinumab; Psoriasis Scalp Severity Index; AEs; adverse events; BSA; body surface area; CI; confidence interval; IGA mod 2011; Investigator's Global Assessment modified 2
IL-23/Th17 targeted therapies in SAPHO syndrome. A case series
Keywords: SAPHO syndrome; IL-23; IL-17; Treatment; Ustekinumab; Secukinumab;
Secukinumab shows significant efficacy in palmoplantar psoriasis: Results from GESTURE, a randomized controlled trial
Keywords: palmoplantar psoriasis; clear or almost clear skin; clinical trial; secukinumab; superiority; quality of life; AE; adverse event; BSA; body surface area; DLQI; Dermatology Life Quality Index; EQ-5D; Euro Quality-of-Life 5-Dimension Health Status Questionn
β-Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis
Keywords: IL-17; psoriasis; secukinumab; β-defensin 2; biomarker; dermal interstitial fluid; microperfusion; psoriatic arthritis; ankylosing spondylitis; rheumatoid arthritis; multiple sclerosis; autoimmunity; AS; Ankylosing spondylitis; BD-2; β-Defensin 2; CD; C
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1Â year: Results from the CLEAR study
Keywords: psoriasis; secukinumab; ustekinumab; clinical trial; Psoriasis Area and Severity Index (PASI); efficacy; safety; AE; adverse event; DLQI; Dermatology Life Quality Index; EQ-5D-3L; EuroQoL 5-Dimension Health Questionnaire 3-level version; HAQ-DI; Health As
Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis
Keywords: long-term safety; phase II studies; phase III studies; pooled analysis; psoriasis; secukinumab; AE; adverse event; ANC; absolute neutrophil count; BCC; basal cell carcinoma; CI; confidence interval; IBD; inflammatory bowel disease; IL; interleukin; IR; in
Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial
Keywords: clear or almost clear skin; clinical trial; head to head; plaque psoriasis; secukinumab; superiority; ustekinumab; 90% or more improvement in baseline Psoriasis Area and Severity Index; AE; adverse event; DLQI; Dermatology Life Quality Index; HRQoL; healt
Secukinumab retreatment-as-needed versus fixed-interval maintenance regimen for moderate to severe plaque psoriasis: A randomized, double-blind, noninferiority trial (SCULPTURE)
Keywords: clinical trial; dosing; immunogenicity; noninferiority; psoriasis; retreatment as needed; secukinumab; AE; adverse event; DLQI; Dermatology Life Quality Index; IGA; investigator global assessment; PASI; Psoriasis Area and Severity Index; PASI 75; 75% or m
Th17 cells and IL-17 A-Focus on immunopathogenesis and immunotherapeutics
Keywords: Th17 cells; Interleukin-17; Secukinumab; Ixekizumab; Brodalumab;